Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial

BACKGROUND: Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC). There are, however, no data about the use of the XELIRI regimen in the neoadjuvant treatment. METHODS: Patients with unresectable liver-o...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Skof, Erik, Rebersek, Martina, Hlebanja, Zvezdana, Ocvirk, Janja
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2009
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2678276/
https://ncbi.nlm.nih.gov/pubmed/19386096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-9-120
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki